Skip to content

Real world study of fluvistrane in the treatment of hormone receptor positive advanced breast cancer

Real world study of fluvistrane in the treatment of hormone receptor positive advanced breast cancer

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100045933
Enrollment
Unknown
Registered
2021-04-29
Start date
2021-05-01
Completion date
Unknown
Last updated
2021-12-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hormone receptor positive advanced breast cancer

Interventions

Sponsors

Mianchi People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
12 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1. Histologically confirmed advanced breast cancer, including inoperable locally advanced breast cancer, newly diagnosed stage IV (according to AJCC 8th Edition) or recurrent / metastatic breast cancer; 2. Estrogen receptor (ER) and / or progesterone receptor (PR) were positive; 3. HER-2 (-) or (1 +) was detected by immunohistochemistry, and HER-2 (2 +) must be detected by fish and the result was negative; 4. All premenopausal patients received ovariectomy or ovarian function inhibitors; 5. Have at least one measurable lesion; 6. The patient voluntarily joined the project and signed the informed consent.

Exclusion criteria

Exclusion criteria: 1. Pregnant or lactating women; 2. Combined chemotherapy; 3. According to the judgment of the researchers, there are serious hazards to the safety of patients or the accompanying diseases that affect the patients to complete the study.

Design outcomes

Primary

MeasureTime frame
Progression-free survival;

Secondary

MeasureTime frame
overall survival;

Countries

China

Contacts

Public ContactMeng Xianlu

Mianchi People's Hospital

1594622530@qq.com+86 13839823992

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026